CMIC, Align Clinical to develop open technology standards for clinical trials

12th July 2019 (Last Updated July 15th, 2019 06:23)

CMIC Group has partnered with Align Clinical to create open technology standards that make it easier for sponsors and contract research organisations (CRO) to work collaboratively during trials.

CMIC, Align Clinical to develop open technology standards for clinical trials
CMIC partners with Align Clinical to develop open technology standards for clinical trials. Credit: Michal Jarmoluk from Pixabay.

CMIC Group has partnered with Align Clinical to create open technology standards that make it easier for sponsors and contract research organisations (CRO) to work collaboratively during trials.

CMIC is the first Japan-based CRO to join the group. It has an expertise of more than 25 years as a solution provider and clinical trial operational expertise in Asia.

The company is collaborating with leading CRO partners to enhance execution and partnership with life sciences companies during clinical trials.

As a provider of end-to-end solutions from preclinical to clinical phase, from drug development to manufacturing stage, and from filing to post marketing surveillance, CMIC acts as a strategic partner to help sponsors develop better medicines faster.

CMIC Holdings president and COO Keiko Oishi said: “The global healthcare industry is going through significant change. The types of service requests and qualification requirements are changing, the number of global trials is increasing, and study designs are more complex.

“As a member of Align Clinical CRO, CMIC is committed to helping the industry increase productivity, reduce operational costs, and run clinical trials more efficiently.”

Founded by Veeva Systems, Align Clinical is  engaged in the improvisation of clinical trial execution and collaboration with life sciences companies.

Established in 1992, CMIC provides comprehensive support services for the development, manufacturing, sales, and marketing of pharmaceutical products. It develops and sells diagnostic pharmaceuticals and orphan drugs.

The group has developed pharmaceutical value creator (PVC) business model which is based on its experience and knowledge as a CRO pioneer.